Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.32
ANGO's Cash-to-Debt is ranked lower than
78% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ANGO: 0.32 )
Ranked among companies with meaningful Cash-to-Debt only.
ANGO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 4.57 Max: N/A
Current: 0.32
Equity-to-Asset 0.74
ANGO's Equity-to-Asset is ranked higher than
73% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ANGO: 0.74 )
Ranked among companies with meaningful Equity-to-Asset only.
ANGO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.84 Max: 0.94
Current: 0.74
0.06
0.94
Interest Coverage 5.68
ANGO's Interest Coverage is ranked lower than
82% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.93 vs. ANGO: 5.68 )
Ranked among companies with meaningful Interest Coverage only.
ANGO' s Interest Coverage Range Over the Past 10 Years
Min: 0.3  Med: 12.23 Max: 31.06
Current: 5.68
0.3
31.06
Piotroski F-Score: 5
Altman Z-Score: 2.77
Beneish M-Score: -3.04
WACC vs ROIC
10.09%
-6.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.97
ANGO's Operating Margin % is ranked higher than
51% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. ANGO: 4.97 )
Ranked among companies with meaningful Operating Margin % only.
ANGO' s Operating Margin % Range Over the Past 10 Years
Min: -10  Med: 2.4 Max: 9.75
Current: 4.97
-10
9.75
Net Margin % -7.66
ANGO's Net Margin % is ranked lower than
64% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.14 vs. ANGO: -7.66 )
Ranked among companies with meaningful Net Margin % only.
ANGO' s Net Margin % Range Over the Past 10 Years
Min: -12.32  Med: 0.16 Max: 6.54
Current: -7.66
-12.32
6.54
ROE % -5.19
ANGO's ROE % is ranked lower than
65% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.92 vs. ANGO: -5.19 )
Ranked among companies with meaningful ROE % only.
ANGO' s ROE % Range Over the Past 10 Years
Min: -8.28  Med: 0.11 Max: 3.22
Current: -5.19
-8.28
3.22
ROA % -3.73
ANGO's ROA % is ranked lower than
61% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. ANGO: -3.73 )
Ranked among companies with meaningful ROA % only.
ANGO' s ROA % Range Over the Past 10 Years
Min: -5.81  Med: 0.07 Max: 2.96
Current: -3.73
-5.81
2.96
ROC (Joel Greenblatt) % 15.64
ANGO's ROC (Joel Greenblatt) % is ranked higher than
57% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.86 vs. ANGO: 15.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANGO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -16.13  Med: 4.83 Max: 35.18
Current: 15.64
-16.13
35.18
3-Year Revenue Growth Rate -0.10
ANGO's 3-Year Revenue Growth Rate is ranked lower than
67% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ANGO: -0.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ANGO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.1  Med: 7.9 Max: 25.2
Current: -0.1
-0.1
25.2
3-Year EBITDA Growth Rate -7.80
ANGO's 3-Year EBITDA Growth Rate is ranked lower than
77% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. ANGO: -7.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANGO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.4  Med: 4.9 Max: 31.9
Current: -7.8
-30.4
31.9
3-Year EPS without NRI Growth Rate 242.90
ANGO's 3-Year EPS without NRI Growth Rate is ranked higher than
98% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. ANGO: 242.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ANGO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: 6.7 Max: 242.9
Current: 242.9
-39.7
242.9
GuruFocus has detected 5 Warning Signs with AngioDynamics Inc $ANGO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANGO's 10-Y Financials

Financials (Next Earnings Date: 2017-04-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ANGO Guru Trades in Q1 2016

Jim Simons 438,500 sh (+20.33%)
Chuck Royce 720,801 sh (+12.48%)
Paul Tudor Jones Sold Out
Mario Gabelli 66,000 sh (-10.81%)
» More
Q2 2016

ANGO Guru Trades in Q2 2016

Joel Greenblatt 14,848 sh (New)
Jim Simons 494,400 sh (+12.75%)
Chuck Royce 752,109 sh (+4.34%)
Mario Gabelli 66,000 sh (unchged)
» More
Q3 2016

ANGO Guru Trades in Q3 2016

Paul Tudor Jones 55,359 sh (New)
Joel Greenblatt 57,378 sh (+286.44%)
Jim Simons 625,846 sh (+26.59%)
Mario Gabelli 66,000 sh (unchged)
Chuck Royce 690,609 sh (-8.18%)
» More
Q4 2016

ANGO Guru Trades in Q4 2016

Joel Greenblatt 61,144 sh (+6.56%)
Chuck Royce 682,548 sh (-1.17%)
Jim Simons 608,646 sh (-2.75%)
Mario Gabelli 60,000 sh (-9.09%)
Paul Tudor Jones 24,974 sh (-54.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ATRC, NAS:OSUR, NAS:NVCR, AMEX:CRHM, NAS:ELGX, OTCPK:NNCSF, NAS:LMNX, OTCPK:GMDTF, NAS:MLAB, NAS:LMAT, NAS:IRTC, NAS:ATRS, NAS:ATRI, NAS:STAA, NAS:PLSE, NAS:ENTL, NAS:UTMD, NAS:CFMS, NAS:DSCI, NAS:SIEN » details
Traded in other countries:UG2.Germany,
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.

AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures & sells medical, surgical & diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease & for use in oncology & surgical settings. Its product offerings fall within three product groupings: Peripheral Vascular, Vascular Access & Oncology/Surgery. The Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. Fluid Management product offering includes the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers & interventional accessories. These devices are utilized together & allow clinicians to aspirate or inject contrast, saline, remove waste & monitor invasive blood pressures throughout the procedure. Venous products focus on the treatment of varicose veins & consist of its VenaCure EVLT laser system & Sotradecol. VenaCure EVLT laser system products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). Sotradecol (sodium tetradecyl sulfate injection) is an FDA approved sclerosing drug that it distribute through a agreement with the manufacturer. Thrombus Management product offerings includes AngioVac & thrombolytic products. In fiscal 2013, the Company released its AngioVac venous drainage system which includes a Venous Drainage Cannula & Cardiopulmonary Bypass Circuit. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, & reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins & surgical bypass grafts. The Company's other core peripheral vascular products include Angiographic products & accessories, drainage, micro access & other products. Angiographic products & accessories are used during peripheral vascular interventional procedures. Drainage products percutaneously drain abscesses & other fluid pockets. An abscess is a tender inflamed mass that typically must be drained by a physician. Image-guided vascular access, or IGVA, involves the use of imaging equipment to guide the placement of catheters that deliver short-term drug therapies, such as chemotherapeutic agents & antibiotics, into the central venous system. The BioFlo products incorporate Endexo Technology into the manufacturing & design of its Vascular Access products. A peripherally inserted central catheter, or PICC, is a long thin catheter that is inserted into a peripheral vein, typically in the upper arm, & until the catheter tip terminates in a large vein in the chest near the heart to obtain intravenous access. Ports are implantable devices utilized

Ratios

vs
industry
vs
history
Forward PE Ratio 22.73
ANGO's Forward PE Ratio is ranked higher than
57% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.77 vs. ANGO: 22.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 12.97
ANGO's Price-to-Owner-Earnings is ranked higher than
85% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.68 vs. ANGO: 12.97 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ANGO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.64  Med: 24.21 Max: 437.5
Current: 12.97
0.64
437.5
PB Ratio 1.19
ANGO's PB Ratio is ranked higher than
82% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.39 vs. ANGO: 1.19 )
Ranked among companies with meaningful PB Ratio only.
ANGO' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 0.97 Max: 3.69
Current: 1.19
0.64
3.69
PS Ratio 1.71
ANGO's PS Ratio is ranked higher than
68% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ANGO: 1.71 )
Ranked among companies with meaningful PS Ratio only.
ANGO' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.67 Max: 4.88
Current: 1.71
1.02
4.88
Price-to-Free-Cash-Flow 13.13
ANGO's Price-to-Free-Cash-Flow is ranked higher than
82% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.63 vs. ANGO: 13.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ANGO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.78  Med: 25.46 Max: 837.6
Current: 13.13
8.78
837.6
Price-to-Operating-Cash-Flow 11.57
ANGO's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.91 vs. ANGO: 11.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ANGO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.4  Med: 15.32 Max: 252.67
Current: 11.57
8.4
252.67
EV-to-EBIT 37.96
ANGO's EV-to-EBIT is ranked lower than
82% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.63 vs. ANGO: 37.96 )
Ranked among companies with meaningful EV-to-EBIT only.
ANGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -253.2  Med: 17.1 Max: 4067.1
Current: 37.96
-253.2
4067.1
EV-to-EBITDA 15.83
ANGO's EV-to-EBITDA is ranked higher than
54% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.65 vs. ANGO: 15.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -874.8  Med: 15.7 Max: 171.6
Current: 15.83
-874.8
171.6
Shiller PE Ratio 4518.76
ANGO's Shiller PE Ratio is ranked lower than
100% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.61 vs. ANGO: 4518.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
ANGO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 39.04  Med: 71.94 Max: 4582.89
Current: 4518.76
39.04
4582.89
Current Ratio 2.91
ANGO's Current Ratio is ranked higher than
63% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.37 vs. ANGO: 2.91 )
Ranked among companies with meaningful Current Ratio only.
ANGO' s Current Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5 Max: 14.28
Current: 2.91
1.95
14.28
Quick Ratio 1.80
ANGO's Quick Ratio is ranked higher than
57% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ANGO: 1.80 )
Ranked among companies with meaningful Quick Ratio only.
ANGO' s Quick Ratio Range Over the Past 10 Years
Min: 1.16  Med: 3.76 Max: 12.12
Current: 1.8
1.16
12.12
Days Inventory 122.61
ANGO's Days Inventory is ranked higher than
53% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. ANGO: 122.61 )
Ranked among companies with meaningful Days Inventory only.
ANGO' s Days Inventory Range Over the Past 10 Years
Min: 116.22  Med: 132.71 Max: 174.24
Current: 122.61
116.22
174.24
Days Sales Outstanding 51.14
ANGO's Days Sales Outstanding is ranked higher than
72% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.14 vs. ANGO: 51.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.92  Med: 56.47 Max: 79.92
Current: 51.14
45.92
79.92
Days Payable 30.53
ANGO's Days Payable is ranked lower than
81% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.97 vs. ANGO: 30.53 )
Ranked among companies with meaningful Days Payable only.
ANGO' s Days Payable Range Over the Past 10 Years
Min: 30.53  Med: 51.69 Max: 110.32
Current: 30.53
30.53
110.32

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
ANGO's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. ANGO: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANGO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29  Med: -12.3 Max: -1
Current: -1.1
-29
-1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 80.48
ANGO's Price-to-Tangible-Book is ranked lower than
98% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. ANGO: 80.48 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ANGO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.58  Med: 3.26 Max: 263.11
Current: 80.48
1.58
263.11
Price-to-Intrinsic-Value-Projected-FCF 1.01
ANGO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
88% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. ANGO: 1.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ANGO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.2  Med: 0.85 Max: 1.09
Current: 1.01
0.2
1.09
Price-to-Median-PS-Value 1.03
ANGO's Price-to-Median-PS-Value is ranked higher than
57% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ANGO: 1.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANGO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.02 Max: 3.13
Current: 1.03
0.67
3.13
Earnings Yield (Greenblatt) % 2.65
ANGO's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. ANGO: 2.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANGO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 4.8 Max: 12.3
Current: 2.65
0.4
12.3
Forward Rate of Return (Yacktman) % 11.58
ANGO's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. ANGO: 11.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ANGO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16  Med: 1.2 Max: 11.9
Current: 11.58
-16
11.9

More Statistics

Revenue (TTM) (Mil) $358.1
EPS (TTM) $ -0.77
Beta0.79
Short Percentage of Float4.33%
52-Week Range $10.71 - 18.18
Shares Outstanding (Mil)37.15

Analyst Estimate

May17 May18
Revenue (Mil $) 359 363
EPS ($) 0.68 0.74
EPS without NRI ($) 0.68 0.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 

More From Other Websites
AngioDynamics to Report Fiscal 2017 Third Quarter Financial Results Mar 20 2017
AngioDynamics Microwave Tissue Ablation System Now CE Marked Mar 15 2017
AngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System Mar 14 2017
AngioDynamics, Inc. breached its 50 day moving average in a Bullish Manner : ANGO-US : March 13,... Mar 13 2017
AngioDynamics to Present at the Barclays Global Healthcare Conference Mar 08 2017
Coverage initiated on AngioDynamics by Barclays Feb 08 2017
AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : January 20,... Jan 20 2017
ETFs with exposure to AngioDynamics, Inc. : January 19, 2017 Jan 19 2017
AngioDynamics, Inc. :ANGO-US: Earnings Analysis: Q2, 2017 By the Numbers : January 17, 2017 Jan 17 2017
ANGIODYNAMICS INC Financials Jan 12 2017
Post Earnings Coverage as AngioDynamics Adjusted EPS Soared 36% Jan 11 2017
ANGIODYNAMICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 10 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AngioDynamics, Inc. for Potential... Jan 09 2017
AngioDynamics (ANGO) Beats Q2 Earnings, Lifts 2017 View Jan 09 2017
Edited Transcript of ANGO earnings conference call or presentation 6-Jan-17 1:00pm GMT Jan 06 2017
ANGIODYNAMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 06 2017
Q2 2017 AngioDynamics Inc Earnings Release - Before Market Open Jan 06 2017
AngioDynamics Reports Fiscal 2017 Second Quarter Results Jan 06 2017
AngioDynamics beats 2Q profit forecasts Jan 06 2017
AngioDynamics beats 2Q profit forecasts Jan 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)